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In this prospective case-control study,
Thompson Legault et al. applied
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genetically homogeneous form of Leigh
syndrome to discover a robust signature
of disrupted oxidative phosphorylation.
The metabolic signature includes
markers of mitochondrial disease,
cardiometabolic risk, and disrupted NAD+
as well as lipid and amino acid
metabolism.
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A decline in mitochondrial respiration represents the
root cause of a large number of inborn errors ofmeta-
bolism. It is also associated with common age-
associated diseases and the aging process. To gain
insight into the systemic, biochemical consequences
of respiratory chain dysfunction, we performed a
case-control, prospective metabolic profiling study
in a genetically homogenous cohort of patients with
Leigh syndrome French Canadian variant, a mito-
chondrial respiratory chain disease due to loss-
of-function mutations in LRPPRC. We discovered
45 plasma and urinary analytes discriminating pa-
tients from controls, including classic markers of
mitochondrial metabolic dysfunction (lactate and
acylcarnitines), as well as unexpected markers of
cardiometabolic risk (insulin and adiponectin), amino
acid catabolism linked to NADH status (a-hydroxy-
butyrate), and NAD+ biosynthesis (kynurenine and
3-hydroxyanthranilic acid). Our study identifies sys-
temic, metabolic pathway derangements that can
lie downstream of primary mitochondrial lesions,
with implications for understanding how the organ-
elle contributes to rare and common diseases.INTRODUCTION
Mitochondrial dysfunction is increasingly being recognized as a
hallmark of rare and common age-associated diseases. AmongCeinherited metabolic diseases, those affecting mitochondria are
the most prevalent worldwide (1:5,000), frequently manifest in
early childhood, and are associatedwith highmorbidity andmor-
tality (DiMauro, 2004; Torraco et al., 2009; Vafai and Mootha,
2013). These disorders may be caused by genetic lesions in
either nuclear or mtDNA, whichmay disrupt numerousmetabolic
pathways housed in the mitochondria but most prominently the
oxidative phosphorylation (OXPHOS) system (Debray et al.,
2008; Munnich and Rustin, 2001). These disorders can impact
virtually any organ system as a whole or in a tissue-specific
manner. A subtle decline in OXPHOS is associated with skeletal
muscle atrophy, type 2 diabetes, neurodegeneration, and the
aging process itself (Vafai andMootha, 2012), though the molec-
ular basis and biochemical consequences are currently not
known. There is growing interest in rare mitochondrial disorders,
and studying themmay shed insight into the role of the organelle
to more common, age-associated disease.
Recently, tremendous progress has been achieved in the
genetic characterization of rare mitochondrial disorders, yet
their management remains challenging because of the difficulty
to track their progression and the absence of proven therapies
(DiMauro and Mancuso, 2007; Orsucci et al., 2009; Pfeffer
et al., 2013; Schapira, 2012). This is due in part to our lack of un-
derstanding of the metabolic consequences of OXPHOS defects
beyond ATP and the commonly reported high blood lactate. In
this regard, the recent emergence of metabolomics technologies
offers a means to systematically measure thousands of low-
molecular-weight compounds in order to provide a global view
of alterations inmetabolic pathways inducedby a given perturba-
tion, whether resulting from a gene mutation or disease onset.
These methods have been applied to numerous diseases such
as diabetes and cardiovascular disease (for reviews, see Roberts
and Gerszten, 2013 and Shah et al., 2012). However, only fewll Reports 13, 981–989, November 3, 2015 ª2015 The Authors 981
Table 1. Clinical Characteristics of LSFC Patients and Matched
Control Individuals
Patients Controls
Gender (male:female) 4:5 4:5
Age, years 22 (6–30) 24 (5–32)
BMI in adults, kg/m2 23.5 (22.3–26.7) 24.0 (21.6–29.2)
BMI for age in children,
percentile
72 (1–96) 70 (2–92)
Serum glucose, mmol/l 4.9 (4.2–5.5) 4.7 (4.4–5.2)
Serum triglycerides, mmol/l 1.32 (0.67–4.18);
3/9
1.12 (0.41–1.55);
1/9
Serum total cholesterol, mmol/l 4.74 (3.53–7.19);
3/9
4.39 (3.47–5.48);
1/9
Serum LDL cholesterol, mmol/l 2.76 (2.08–4.52);
3/8a
2.45 (1.59–3.45);
2/9
Serum HDL cholesterol, mmol/l 1.01 (0.76–1.49);
2/9b
1.46 (1.13–2.19)
Serum total cholesterol/
HDL ratio
4.23 (3.13–7.33)b 3.11 (2.05–3.96)
Serum AST, U/l 23 (14–30) 24 (12–91); 1/9
Serum ALT, U/l 21 (14–51); 1/9 18 (14–58); 2/9
Serum GGT, U/l 11 (8–86); 1/9 13 (6–37)
Plasma insulin, mU/l 10.3 (3.8–26.2)b 4.79 (3.2–11.9)
Plasma adiponectin, ng/ml 4,200 (1,304–
10,410)b
10,229 (3,580–
37,804)
Data presented as median (min-max) and, where applicable, proportion
of abnormal results when measured as part of the routine biochem-
ical assay. Subjects’ characteristics are described in more details in
Table S1.
aData for LDL cholesterol were missing for one patient given that triglyc-
eride level was too high.
bp < 0.03 patients versus controls following permutation test (Platform 1).studies have extended this method to mitochondrial disorders
(Clarke et al., 2013; Leoni et al., 2012; Shahamet al., 2010), which
pose significant challenges, owing to their genotypic and pheno-
typic heterogeneity combined with small patient populations.
To overcome these challenges, we performed metabolic
profiling in a small but genetically defined cohort of patients
with Leigh syndrome French Canadian variant (LSFC; MIM no.
220111). First described in 1993 (Merante et al., 1993; Morin
et al., 1993), LSFC is a recessive disorder prevalent in the north-
eastern regionofQuebec (1/2,000births; carrier rate 1/23) (Mer-
ante et al., 1993; Morin et al., 1993). LSFC patients exhibit many
hallmarks of mitochondrial disorders, including lactic acidosis
and Leigh syndrome, a necrotizing encephalopathy (Debray
et al., 2011; Finsterer, 2008;Morin et al., 1993). LSFCwas the first
human disorder whose underlying genetic locuswasmapped via
linkage disequilibrium (also known as genome-wide association
study; Lee et al., 2001) and the underlying gene discovered via
‘‘integrative genomics’’ (Mootha et al., 2003). All known cases
are due to missense (A354V) or deletion (C1277STOP) mutations
in the nuclear leucine-rich pentatricopeptide-repeat-motif-con-
taining (LRPPRC) gene, which encodes amitochondrial localized
RNA-binding protein. These mutations lead to a tissue-specific
impact on mitochondrial OXPHOS complexes (Gohil et al.,982 Cell Reports 13, 981–989, November 3, 2015 ª2015 The Authors2010; Mourier et al., 2014; Ruzzenente et al., 2012; Sasarman
et al., 2010, 2015; Xuet al., 2004).More recently, LSFCfibroblasts
were found to display multiple alterations in mitochondrial func-
tion and increased susceptibility to nutrient-induced cytotoxicity,
particularly saturated fat (Burelle et al., 2015).
We recruited all known LSFC patients and, using a pro-
spective, case-control study design, we performed metabolic
profiling in plasma and urine using two different targeted mass
spectrometric (MS)-based methods. We report a metabolic
signature consisting of 45 compounds or ratios that distinguish
LSFC patients from controls. The metabolites provide insight
into the metabolic pathway derangements that ensue from a
root mitochondrial lesion and provide a valuable resource for
understanding the biochemical consequences and basis of
mitochondrial dysfunction.
RESULTS
We performed metabolic profiling of all known living patients
with LSFC. Eight of the nine patients are homozygotes for the
A354V foundermutation, and one patient is compound heterozy-
gous for this mutation and a premature stop (Mootha et al.,
2003). Our study design is described in Experimental Proce-
dures and depicted in Figure S1. Patients were prospectively
matched with controls for gender, age, BMI, physical activity
level, and nutritional status. Metabolic measurements encom-
passed standard clinical biochemical parameters and multiple
metabolite classes in plasma and urine. These analyses gener-
ated two independent data sets, hereafter referred to as ‘‘plat-
forms,’’ which were processed through a statistical workflow
for quality control filtering, missing data imputation, principal
component analysis (PCA), and permutation testing. Signifi-
cance threshold was set at a false discovery rate of 10%, cor-
responding to a p value < 0.03 for Platform 1 and <0.023 for
Platform 2. Characteristics of LSFC patients and controls are
summarized in Table 1 and described in more detail in Table
S1. As expected given the intendedmatching, there were no sta-
tistical differences between patients and controls for age, BMI,
or physical activity (paired t test; a = 0.05).
Clinical Biochemical Assays in LSFC Patients versus
Controls
Standard biochemical and hormonal assays, measured as
part of Platform 1, showed that LSFC patients had significantly
increased total cholesterol/HDL ratio and insulin levels, as well
as reduced levels of HDL cholesterol and adiponectin. A trend
for a significant increase in triglyceride levels was also observed
(p = 0.039; Tables 1 and S2), whereas serum glucose was similar
to controls (p = 0.320). Collectively, these changes would sug-
gest an increased cardiometabolic risk (Leiter et al., 2011) in
LSFC patients.
Global Metabolic Profiles in LSFC versus Controls
PCA was first applied to the post-quality control, imputed data
set from each platform, namely 137 analytes including standard
biochemistry and hormones for Platform 1 and 156 for Plat-
form 2, with an overlap of 37 metabolites between the two plat-
forms. As shown in Figure 1, the first PC from each platform
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Figure 1. Principal-Component Analysis
Discriminates LSFC Patients and Controls
For each panel, the post-quality control, imputed
data set was used to perform the analysis.
(A) Platform 1; PC1 and PC2 account for 18% and
13% of variation, respectively.
(B) Platform 2; PC1 and PC2 account for 17% and
14% of variation, respectively.
Loading scores are reported in Table S3; see also
Figure S1 for an overview of analytes submitted to
the PCA and Table S2 for raw data sets.fully discriminated patients from controls, indicating a distinct
metabolic profile in LSFC patients. In each data set, the top
two PCs accounted for 31% of the total variation (see Table
S3 for loading scores). Metabolites contributing the most to
the separation included lactate, b-hydroxybutyrate, acylcarni-
tines of various chain lengths, and a-hydroxybutyrate; to the
best of our knowledge, the latter has not been previously re-
ported in plasma from patients with an inherited mitochondrial
disorder.
The two data sets were then independently subjected to
permutation analyses, and statistical significance was reached
between patients and controls for 24 analytes/ratios out of 137
in Platform 1 (p < 0.03) and for 31 analytes out of 156 in Platform
2 (p < 0.023), with an overlap of nine significant metabolites
between both platforms (Table S4). All analytes are depicted
as volcano plots in Figure S2 and listed in Table S2. Combining
the results of both platforms, 46 single variables (representing
45 unique compounds/ratios) out of the 256 single variables
submitted to the permutation test were statistically different
between LSFC patients and controls, as depicted in Figure 2.
Of note, the compound heterozygote was similar to the other
LSFC patients (A354V homozygotes).
Concurring with the multivariate PCA, the most striking differ-
ences were observed for (1) plasma b-hydroxybutyrate and
lactate, as well as the b-hydroxybutyrate/acetoacetate ratio;
(2) acylcarnitines, and more specifically myristoylcarnitine and
palmitoylcarnitine (C14 and C16, respectively); and (3) a-hy-
droxybutyrate (Figure 2). Altogether, the changes in metabolite
levels can be organized into a small handful of metabolic
pathways. First, these include elevated NADH/NAD+ ratio
(increased b-hydroxybutyrate, lactate, and b-hydroxybutyrate/
acetoacetate ratio) and closely related alterations in citric acid
cycle (CAC) reactions, including those catalyzing entry or
removal of carbons from this cycle (increased isocitrate, malate,
and propionate, albeit decreased succinate and methylmalo-
nate). Then, elevated C2, C6, C12, C14, C14:1, C16, C18:1,
and C18:2 acylcarnitine but decreased C9 and C10:2 species
reflect disrupted fatty acid oxidation, whereas impaired biosyn-
thesis is suggested by increased vaccenic acid (C18:1n-7),
dihomo-g-linolenic acid (C20:3n-6), and phosphoethaloamine.
Of particular interest, there were also unexpected changes in
plasma metabolites relevant to amino acid catabolism, further
substantiating the complexity of metabolic perturbations linked
to NAD+ metabolism. These include (1) an increase in a-hydrox-
ybutyrate, a metabolite arising from the reduction of a-keto-Cebutyrate formed from methionine and/or threonine, and (2)
various intermediates of the tryptophan degradation pathways
involved in NAD+ synthesis (kynurenine and 3-hydroxyanthra-
nilic acid) or product of gut bacterial metabolism (indoxyl sul-
fate; Zhu et al., 2011). Finally, LSFC patients displayed
increased plasma levels of creatine and decreased levels of
the bile acid glycocholate, observations that were also made
in patients affected by various OXPHOS defects (Pajares
et al., 2013; Shaham et al., 2010) and with mutations in mito-
chondrial pantothenate kinase 2 (PANK2) (the rate-limiting
enzyme in mitochondrial coenzyme A biosynthesis; Leoni
et al., 2012), respectively.
Quantitative Analyses of Metabolic Indices
of NADH/NAD+
Because both PCA and permutation tests revealed that a
perturbed redox status was a prominent feature of the distinctive
metabolic signature in LSFC patients, an isotope dilution GC-MS
method was developed in order to quantify with precision lactate
and b-hydroxybutyrate as well as their corresponding oxidized
counterparts, namely pyruvate and acetoacetate, respectively.
In addition, we included a-hydroxybutyrate, a finding issued
from the metabolic profiling on Platform 2 but that was not as-
sessed on Platform 1, because we suspected that its elevation
was also linked to the increased NADH/NAD+ ratio. Hence, it
was measured along with its oxidized counterpart, namely a-ke-
tobutyrate. The results of these analyses are consistent with the
initial metabolic profiling data. In fact, the plasma concentration
of lactate, pyruvate, b-hydroxybutyrate, and a-hydroxybutyrate,
as well as the lactate/pyruvate and b-hydroxybutyrate/ace-
toacetate ratios, were all significantly higher in LSFC patients
(Figure 3). Importantly, this analysis revealed that the a-hydrox-
ybutyrate/a-ketobutyrate ratio was also significantly increased.
Collectively, these quantitative measurements further support
the findings of an elevated plasma level of a-hydroxybutyrate
in LSFC patients, revealing an additional metabolic perturbation
linked to the altered redox status in these patients.
DISCUSSION
In this prospective study, we applied a comprehensive targeted
metabolomics approach to a genetically homogenous cohort of
patients with an inherited mitochondrial respiratory chain disor-
der. Despite a small sample size, the current case-control
study design enabled the identification of a distinct metabolicll Reports 13, 981–989, November 3, 2015 ª2015 The Authors 983
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Figure 2. Individual Analytes with Statistical
Significance in LSFC Patients versus Con-
trols
(A) Platform 1; (B) Platform 2. Each dot represents
a log2-transformed patient/matched control ratio.
Metabolites are ordered by mean log2-trans-
formed patient/control ratio. See also Figure S2 for
data presented as volcano plots, Figure S1 for a
summary of measured analytes, and Table S2
for log2-transformed ratios and p values of all
analytes.signature, consisting of 45 compounds spanning indices of car-
diometabolic risk, disrupted NADH/NAD+, as well as lipid and
amino acid metabolism.
Markers of Increased Global Cardiometabolic Risk
Much to our surprise, a disturbed cholesterol profile along
with alterations in insulin and adiponectin levels were found,
suggesting an increased global cardiometabolic risk in LSFC
patients despite their relatively young age (Leiter et al., 2011).
Although diabetes has been strongly associated with mutations
in some mtDNA-encoded genes (Maassen et al., 2004), dyslipi-
demia has only been previously reported in few other cohorts
of patients with respiratory chain disorders (Clarke et al.,
2013; Finsterer et al., 2001; Kaufmann et al., 2009). In LSFC
patients, increased cardiometabolic risk is further supported
by the higher plasma levels of the fatty acids vaccenic and
dihomo-g-linolenic acids (C18:1n-7 and C20:3n-6, respec-
tively), which have both been recognized as markers of insulin
resistance (Lovejoy et al., 2001; Zulyniak et al., 2012). Interest-
ingly, phosphoethanolamine, of which plasma levels were
also increased, may also be associated with these alterations.
This metabolite is an intermediate in the biosynthesis of phos-
phatidylethanolamine through the CDP-ethanolamine pathway
(‘‘Kennedy pathway’’), and transgenic mice heterozygous for
Pcyt2—a gene involved in this pathway that leads to increased
hepatic phosphoethanolamine synthesis—display progressive
hypertriglyceridemia, insulin resistance, as well as liver steatosis
(Fullerton et al., 2009), which is also a characteristic found in
LSFC patients (Morin et al., 1993).
Disturbances in Pathways Related to Energy
Metabolism and the NADH/NAD+ Ratio
As expected, lactate, pyruvate, and alanine were elevated in
LSFC patients as compared with controls, as it has often been
reported in patients with mitochondrial diseases, although these984 Cell Reports 13, 981–989, November 3, 2015 ª2015 The Authorsmetabolites might not be specific to mito-
chondrial dysfunction (Debray et al., 2008;
Haas et al., 2008; Smeitink et al., 2006).
Our quantitative analyses further substan-
tiated elevated plasma lactate/pyruvate
and b-hydroxybutyrate/acetoacetate ra-
tios, hence reflecting an accumulation of
reducing equivalents in the cytosol and
mitochondria, respectively. Elevations in
blood CAC intermediates and saturatedeven chain acylcarnitines have previously been reported in pa-
tients with mitochondrial disorders (Haas et al., 2008; Smeitink
et al., 2006). The elevation in acylcarnitines of all chain lengths
in LSFC patients reflects a global disturbance of mitochondrial
fatty acid b-oxidation, suggesting an impaired lipid-handling
capacity (Adams et al., 2009; Houten and Wanders, 2010). This
concurs with our recent finding of an increased susceptibility to
palmitate-induced cytotoxicity in LSFC fibroblasts and is consis-
tent with a tissue-specific defect in complex IV alone (for e.g.,
fibroblasts; Burelle et al., 2015) or combinedwith complex I (mus-
cle and liver; Sasarmanet al., 2010, 2015). The situation is likely to
differ for complex I defects alone, which still enable entry of
reducing equivalents arising from fatty acid oxidation at complex
II and electron flux through complexes II–V and for which a pos-
itive effect of high-fat diets hasbeenobserved (Schiff et al., 2011).
Our systematic metabolomics approach also revealed an
unexpected decrease in decadienoylcarnitine (C10:2) and nona-
noylcarnitine (C9). The decrease in C10:2-carnitine, a partial
oxidation product of the essential fatty acid linoleate (C18:2n-6),
would suggest an increase in 2,4-dienoyl-CoA reductase activity
that may be driven by an elevated NADPH/NADP ratio resulting
from mitochondrial redox perturbation (Miinalainen et al., 2009).
As for C9-carnitine, the metabolic origin of this compound is un-
clear, although it was suggested to be formed from the combined
peroxisomal and mitochondrial catabolism of phytanic and pris-
tanic acids, two branched chain fatty acids (Verhoeven et al.,
1998). A decrease in C9-carnitine has also been reported in fibro-
blasts from patients with mitochondrial trifunctional protein defi-
ciency (Roe et al., 2006), a fatty acid oxidation disorder. The latter
findings emphasize the diversity of perturbations in fatty acid
oxidation, which can result from mitochondrial dysfunction.
Perturbations in Amino Acid Metabolic Pathways
Beyond markers of mitochondrial energy metabolic path-
ways, other unexpected changes reflecting perturbations in
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Figure 3. Quantitative Profiling of Metabolites Reflective of NADH/
NAD+ Redox Status
Metabolites are shown in scatter dot plots with line indicating the mean. *p <
0.05 patients versus controls. See also Table S2 for raw data.the metabolism of several amino acids were observed in LSFC
patients. These include higher plasma levels of a-hydroxybuty-
rate. However, its oxidized metabolite counterpart, namely
a-ketobutyrate, which arises from the catabolism of the essen-
tial amino acids threonine and/or methionine in the cytosol
(Landaas, 1975), did not differ; consequently, the a-hydroxy-
butyrate/a-ketobutyrate ratio was also significantly elevated.
Whereas these findings likely represent another consequence
of an elevated NADH/NAD+ ratio, the higher level of a-hydrox-
ybutyrate also highlights major critical perturbations in its meta-
bolism. The latter is depicted in Figure 4 along with changes in
closely related metabolites. Similarly to pyruvate, a-ketobuty-
rate is at a metabolic crossroad between the cytosol and the
mitochondria. It may be transported to the mitochondria and
subjected to oxidative decarboxylation to form propionyl-
CoA; these steps are likely catalyzed by the pyruvate trans-
porter and the branched-chain a-keto acid dehydrogenase
complex (Jakobs et al., 1977; Paxton et al., 1986; Smith and
Strang, 1958; Steele et al., 1984). Alternatively, a-ketobutyrate
may be reduced to a-hydroxybutyrate by lactate dehydroge-Cenase or b-hydroxybutyrate dehydrogenase (Rosalki and Wilkin-
son, 1960).
A few studies have reported increased a-hydroxybutyrate
in patients with inherited metabolic diseases, such as lactic
acidosis (Pettersen et al., 1973) ormaple syrup urine disease (Ja-
kobs et al., 1977; Smith and Strang, 1958). More recently, this
metabolite has been reported to represent a strong and early
marker of insulin resistance and glucose intolerance (Adams,
2011; Ferrannini et al., 2013; Fiehn et al., 2010; Gall et al.,
2010; Xu et al., 2013) and was suggested as a potential
biomarker for the diagnosis of metabolic syndrome (Demine
et al., 2014; Lin et al., 2014). Factors proposed to play a role in
a-hydroxybutyrate accumulation in plasma include perturba-
tions in branched-chain amino acid catabolism, hepatic gluta-
thione synthesis, or redox status (Gall et al., 2010; Landaas,
1975). Whereas the exact mechanisms underlying its elevation
in LSFC patients remain to be elucidated, the present findings
do not support a central role for branched-chain amino acids
as proposed for insulin-resistant subjects (Adams, 2011; New-
gard, 2012), because their levels were similar between LSFC
patients and controls. Furthermore, whereas impaired gluta-
thione metabolism has been reported in children with classical
Leigh syndrome (Pastore et al., 2013), levels of reduced and
oxidized glutathione in our LSFC cohort were similar to controls,
suggesting that oxidative stress was not increased. This obser-
vation is consistent with our recent finding in LSFC fibroblasts
(Burelle et al., 2015) but contrasts with those reported for other
OXPHOSdefects, namely complex I and III (Diaz et al., 2012; Dis-
telmaier et al., 2009; Koene et al., 2011). It is noteworthy that the
plasma level of malondialdehyde was significantly increased in
LSFC patients, albeit this is not a specific oxidative stress
marker, because it is also generated by cyclo-oxygenases in
thromboxane metabolism (Kadiiska et al., 2005). An accelerated
methioninemetabolism through the S-adenosylmethionine cycle
in LSFC patients is, however, suggested by the increased
plasma levels of creatine, which may reflect a low intracellular
energy status (Shaham et al., 2010). This may also suggest a
perturbation in methylation reactions, which could impact on
signaling pathways regulating cellular survival or mitochondrial
biogenesis such as Sirt1 and/or PGC-1a (Gue´ant Rodriguez
et al., 2013).
Our results also demonstrate alterations in the metabolism of
tryptophan (reduced kynurenine and 3-hydroxyanthranilic acid)
and aspartate (increased N-acetylaspartate), which have been
linked to neurodegeneration (Sas et al., 2007; Tan et al., 2012),
an important clinical feature of LSFC. Among intermediates of
the tryptophan catabolic pathways that lead to NAD+ synthesis,
kynurenine and 3-hydroxyanthranilic acidwere significantlymodi-
fied (Figure 4), although tryptophan itself or other metabolites of
thispathwaywereunchanged.As forN-acetylaspartate, it is found
exclusively in neurons and arises from the condensation of aspar-
tateandacetyl-CoA in themitochondria. Its increased level inurine
has been reported in patients with aspartoacylase deficiency
(Canavan disease), a leukodystrophy characterized by neurode-
generation and early death (Al-Dirbashi et al., 2007). In the brain,
its elevation has been reported as a marker of compromised
neuronal integrity, but reduction suggests neurodegenerative dis-
orders (Knapman et al., 2012; Moreno et al., 2001).ll Reports 13, 981–989, November 3, 2015 ª2015 The Authors 985
Figure 4. Pathway Relationship of Major
Metabolic Alterations in LSFC Patients
This scheme depicts pathways related to reported
perturbations in cytosolic and mitochondrial NADH
accumulation, disrupted citric acid cycle (CAC),
fatty acid b-oxidation, and amino acid metabolism,
with a specific emphasis on those linked to a-hy-
droxybutyrate formation. Metabolites whose levels
increased are indicated in red and with an upward
arrow; those whose levels decreased are indicated
in green and with a downward arrow. Metabolites
whose levels did not change significantly are indi-
cated in black with a sideways arrow. Those me-
tabolites that were not measured are indicated in
black (with no arrow). See also Figure S1 for an
overview of analytes measured in the study and
Table S2 for raw data and p values.Conclusions
This study highlights the power of metabolomics when applied in
a prospective case-control design to a genetically homogenous
form of Leigh syndrome presenting with many of the hallmark
features of mitochondrial respiratory chain disease. Results
uncovered a LSFC metabolic signature including both classic
and unexpected metabolites, which collectively highlight the
complexity of perturbations that may result from mitochondrial
dysfunction but also have implications for understanding po-
tential contributions of mitochondrial dysfunction to common
disease. Altogether, this signature concurs with the reported
tissue-specific impact of mutated LRPPRC on mitochondrial
OXPHOS complexes (Mourier et al., 2014; Sasarman et al.,
2010, 2015) and function in LSFC fibroblasts (Burelle et al.,
2015), while representing also possible targets for intervention.
Future studies will be needed in order to further delineate the
underlying metabolic mechanisms and further characterize
whether the identified metabolites may be relevant as biological
markers for the assessment of severity, prediction of lactic
acidosis crises, monitoring of disease progression, or response
to interventions in patients with LSFC and, possibly, other in-
herited mitochondrial disorders.EXPERIMENTAL PROCEDURES
Subjects, Sample Collection, and Genotyping
LSFC patients were included based on medical history and genetic testing
for the A354V and C1277STOP mutations in LRPPRC. Matching criteria for986 Cell Reports 13, 981–989, November 3, 2015 ª2015 The Authorscontrols included gender, age (±2 years for chil-
dren <18 years; ±5 years for adults), BMI (±10 per-
centiles of BMI for age for children; ±3 kg/m2 for
adults), and physical activity level (see the Sup-
plemental Experimental Procedures for details).
Carrying A354V or C1277STOP mutation was an
exclusion criterion for controls. The protocol was
approved by the Human Ethics and Research
Committee of the Centre de Sante´ et de Services
Sociaux de Chicoutimi. Written informed consent
was obtained for all study participants or their
legal guardians, and assent was obtained when
applicable. Metabolic profiling was performed on
venous blood and urine samples collected afteran overnight fast of minimum 12 hr, during which water was allowed. Genotyp-
ing was performed on saliva samples. Samples were processed as described
in the Supplemental Experimental Procedures.
Metabolite Profiling and Quantitative Analysis
The overall workflow for metabolic profiling is depicted in Figure S1 and
described in detail in the Supplemental Experimental Procedures. This was
performed using a combination of standard biochemical and hormonal assays
as well as established targeted GC-MS and LC-MS methods, altogether en-
compassing 407 analytes, which were treated as two distinct platforms. Plat-
form 1 included clinical laboratory assays, hormonal assays, and MS-based
profiling of amino acids, fatty acids, organic acids, and acylcarnitines. For Plat-
form 2, two LC-MS methods were used to profile polar metabolites. After ob-
taining data from Platforms 1 and 2, a quantitative isotope dilution GC-MS
method was developed to quantify plasma metabolites specifically reflecting
cellular redox state, based on a previously published method (Lauzier et al.,
2013).
Data Mining and Statistical Analysis
Results from Platform 1 and Platform 2 were treated as two distinct data sets
to which the statistical workflow was applied using R 3.0.2 (R Foundation for
Statistical Computing) for quality control filtering, log2-transformation, and
missing data imputation (see the Supplemental Experimental Procedures).
Raw data for all measured metabolites are provided in Table S2. The post-
quality control, imputed data sets were submitted to PCA (SIMCA-P+ 13.0;
Umetrics) and permutation test between the two groups. All possible distinct
permutations were conducted within patients/control pairs, for a total of 256
(28). The significance threshold was determined according to the estimation
of true and false positives and was established in order to correspond to an
estimated false discovery rate of 10%. This led to a p threshold of <0.03 for
Platform 1 and 0.023 for Platform 2. For the quantitative profiling of selected
metabolites, p values were generated by a permutation test, and a threshold
of 0.05, corresponding to a false discovery rate of 5.7%, was used to control
for type 1 error.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
two figures, and four tables and can be found with this article online at
http://dx.doi.org/10.1016/j.celrep.2015.09.054.
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Catherine Laprise, Genevie`ve Lavalle´e, Pierre Lavoie, BrunoMaranda, Charles
Morin, Yvette Mukaneza, Tamiko Nishimura, John D. Rioux, Marie-E`ve Rivard,
Florin Sasarman, Eric A. Shoubridge, Jessica Tardif, Julie Thompson Legault,
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leneuve. Affiliations are listed in the Supplemental Information along with indi-
vidual author contributions.
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